# VisionCare

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/visioncare

- Industry: Medical Devices & Equipment
- Headquarters: Saratoga, US
- Website: www.visioncareinc.net
- Total disclosed funding: $80M
- Latest round: Series E (Jan 23, 2012)
- Investors on record: 14

## About

VisionCare, Inc. focuses on developing innovative ocular devices that enhance and restore vision, particularly for those affected by age-related macular degeneration and severe visual impairments.VisionCare, Inc., founded in 1997, specializes in advanced ocular solutions. Headquartered in Saratoga, US, the company has completed 9 deals, with the most recent being a VENTURE DEBT round raising USD 15.00 mn in December 2014 from Life Sciences Alternative Funding. The CEO is Tom Ruggia.VisionCare Inc. specializes in providing advanced ocular devices and solutions designed to enhance and restore vision. Their core product offerings include state-of-the-art intraocular telescopes and other vision-enhancing technologies aimed at treating age-related macular degeneration (AMD) and other severe visual impairments. These devices function by magnifying images and projecting them directly onto the retina, thereby improving the visual experience for individuals suffering from specific eye conditions. The company primarily serves ophthalmologists, optometrists, and healthcare facilities across North America and select international markets, including Europe and Asia. VisionCare Inc. has positioned itself as a leader in specialized vision care, catering to a diverse clientele that includes patients, healthcare providers, and rehabilitation centers dedicated to improving quality of life for those facing visual challenges.VisionCare Inc. generates revenue through a structured business model that emphasizes direct sales to healthcare providers and partnerships with medical facilities. Transactions typically involve the sale of devices through B2B interactions, where healthcare providers purchase intraocular telescopes and related products for patient use. Clients may place orders based on individual patient needs, with pricing structures set to ensure accessibility while maintaining product integrity. VisionCare Inc. also engages in collaborative initiatives with healthcare organizations to facilitate the distribution and implementation of their flagship products. This model allows the company to maintain a consistent revenue stream by fostering long-term relationships with healthcare professionals and institutions that prioritize innovative vision care solutions.VisionCare Inc. aims to expand its product line and explore new markets following their latest funding round in December 2014. The company plans to develop and launch new vision-enhancing products and target expansion into international markets, specifically in Europe and Asia, by 2025. The recent VENTURE DEBT round, raising USD 15.00 mn, will be utilized to support these product development initiatives and market entry strategies.

## Funding rounds

- Series E, Jan 23, 2012, $4M — Agate Medical Investments
- Series E, Jan 10, 2011, $31M — Pitango, Giza Venture Capital, Three Arch Partners, Saints Capital, ONSET Ventures, BSI Bank, Generali Financial Holdings, Newbury Acquisitions Fund/Infinity CSVC Management
- Series D, Dec 15, 2004, $20M — Pitango, Three Arch Partners, Infinity Group, Boston Scientific, ONSET Ventures
- Series C, Nov 2, 2003, $12M — Pitango, Three Arch Partners, ONSET Ventures, Headline [DUP]
- Series C, Jul 1, 2002, $6.8M — Pitango, Three Arch Partners, ONSET Ventures
- Series A, Dec 1, 1999, $6M — Pitango, Clal Industries and Investments, Peregrine Ventures

## Investors

- Pitango (https://capitalatlas.ai/funds/pitango) — Series A, Series C, Series D, Series E
- Clal Industries and Investments — Series A
- Peregrine Ventures (https://capitalatlas.ai/funds/peregrine-ventures) — Series A
- Three Arch Partners (https://capitalatlas.ai/funds/three-arch-partners) — Series C, Series D, Series E
- ONSET Ventures (https://capitalatlas.ai/funds/onset-ventures) — Series C, Series D, Series E
- Headline [DUP] — Series C
- Infinity Group (https://capitalatlas.ai/funds/infinity-group) — Series D
- Boston Scientific — Series D
- Giza Venture Capital (https://capitalatlas.ai/funds/giza-venture-capital) — Series E
- Saints Capital (https://capitalatlas.ai/funds/saints-capital) — Series E
- BSI Bank — Series E
- Generali Financial Holdings — Series E
- Newbury Acquisitions Fund/Infinity CSVC Management — Series E
- Agate Medical Investments (https://capitalatlas.ai/funds/agate-medical-investments) — Series E